ARTICLE
18 April 2017

Drug, Device Makers Could Get Hit for Not Reporting Payments to Doctors

DP
Day Pitney LLP

Contributor

Day Pitney LLP logo
Day Pitney LLP is a full-service law firm with more than 300 attorneys in Boston, Connecticut, Florida, New Jersey, New York and Washington, DC. The firm offers clients strong corporate and litigation practices, with experience on behalf of large national and international corporations as well as emerging and middle-market companies. With one of the largest individual clients practices on the East Coast, the firm also has extensive experience assisting individuals and their families, fiduciaries and tax-exempt entities plan for the future.
Day Pitney healthcare attorney Eric Fader was quoted in an April 12 article, "Drug, Device Makers Could Get Hit for Not Reporting Payments to Doctors," in Bloomberg BNA's Life Sciences Law & Industry Report and other publications.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

Day Pitney healthcare attorney Eric Fader was quoted in an April 12 article, "Drug, Device Makers Could Get Hit for Not Reporting Payments to Doctors," in Bloomberg BNA's Life Sciences Law & Industry Report and other publications. Eric spoke with Bloomberg BNA about the Open Payments program, which requires drug and medical device makers to report all payments to physicians and teaching hospitals for provider education, travel, and compensation for speaking engagements.

The Open Payments program was created under the Affordable Care Act and could be eliminated if the ACA is repealed, but Eric said it appears that no immediate changes are in store. "President Trump's promises to rein in drug prices suggest that his administration will favor continued or even increased disclosure requirements for pharma and device companies," he said.

Payment information for 2016 will be released on the Centers for Medicare & Medicaid Services' website in June and CMS has redesigned the site and upgraded how users can display the data, but problems may still arise, Eric told Bloomberg BNA. "This year's data will undoubtedly continue to be difficult to analyze and misleading in spots, especially when larger companies spread their reporting under multiple subsidiaries, or use multiple names for the same drugs when they're marketed for different conditions," Eric said.


For more articles and regular updates on legislative changes, regulatory developments and other news of interest to businesses, professionals and investors in the healthcare industry, please subscribe to Day Pitney's mailing lists.


Click here for more Healthcare Blogs from Day Pitney

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More